UNITY Biotechnologies has recently announced an expansion of its first-stage human trial of UBX0101, a drug that has been shown to have senolytic properties in mice [1] and that the company hopes will be useful in treating painful osteoarthritis of the knee. An expanded clinical trial UNITY Biotechnologies, a $495 million biotech company in the…

Another senolytic drug candidate has entered development at Unity Biotechnologies. The purpose of senolytics is to clear the body of harmful senescent cells, which accumulate with age and encourage age-related diseases to develop. A new treatment for age-related diseases of the eye Recently, UNITY Biotechnologies announced the selection of a new lead drug, UBX1967, with…

Senolytics are the first therapies that directly target an aging process in order to delay or prevent age-related diseases, and they are now in human trials. Today, we think that it is the ideal time to have a look at how they work and what companies are involved. Senescent cells and aging As we get…

July is here, and our upcoming conference in New York City is only a handful of days away! If you haven’t done so already, go and get your ticket now so that you can enjoy the June roundup fully relaxed, knowing that your seat is secured. About our NYC conference On the off chance you’ve…

Today we are pleased to announce that UNITY Biotechnology is going into human clinical trials with the first true rejuvenation therapy that directly targets one of the processes of aging: senescent cells. The quiet revolution In our collective imagination, revolutions start with a bang; however, more often than not, real-life technological revolutions start quietly and…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD